<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="case-report"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Hematol Rep</journal-id><journal-id journal-id-type="iso-abbrev">Hematol Rep</journal-id><journal-id journal-id-type="publisher-id">hematolrep</journal-id><journal-title-group><journal-title>Hematology Reports</journal-title></journal-title-group><issn pub-type="ppub">2038-8322</issn><issn pub-type="epub">2038-8330</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40407635</article-id><article-id pub-id-type="pmc">PMC12101316</article-id>
<article-id pub-id-type="doi">10.3390/hematolrep17030025</article-id><article-id pub-id-type="publisher-id">hematolrep-17-00025</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>Severe Aplastic Anemia Complicated with Fatal Invasive Fungal Infections in a Young Patient Harboring Perforin Gene Polymorphisms</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0007-0989-8346</contrib-id><name><surname>Krithinaki</surname><given-names>Maria I.</given-names></name><xref rid="af1-hematolrep-17-00025" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Kokkinakis</surname><given-names>Ioannis</given-names></name><xref rid="af2-hematolrep-17-00025" ref-type="aff">2</xref><xref rid="fn1-hematolrep-17-00025" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5214-0011</contrib-id><name><surname>Markatzinou</surname><given-names>Styliani</given-names></name><xref rid="af3-hematolrep-17-00025" ref-type="aff">3</xref><xref rid="fn1-hematolrep-17-00025" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Masaoutis</surname><given-names>Christos</given-names></name><xref rid="af4-hematolrep-17-00025" ref-type="aff">4</xref><xref rid="fn1-hematolrep-17-00025" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Solomou</surname><given-names>Elena</given-names></name><xref rid="af5-hematolrep-17-00025" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Papakitsou</surname><given-names>Ioanna</given-names></name><xref rid="af6-hematolrep-17-00025" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name><surname>Xirouchaki</surname><given-names>Nektaria</given-names></name><xref rid="af6-hematolrep-17-00025" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name><surname>Liapis</surname><given-names>Ioannis</given-names></name><xref rid="af7-hematolrep-17-00025" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5146-9699</contrib-id><name><surname>Papadaki</surname><given-names>Helen A.</given-names></name><xref rid="af1-hematolrep-17-00025" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0002-7198-3887</contrib-id><name><surname>Pontikoglou</surname><given-names>Charalampos G.</given-names></name><xref rid="af1-hematolrep-17-00025" ref-type="aff">1</xref><xref rid="c1-hematolrep-17-00025" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Angelucci</surname><given-names>Emanuele</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-hematolrep-17-00025"><label>1</label>Department of Hematology, School of Medicine, University of Crete, University General Hospital of Heraklion, 71500 Heraklion, Greece; <email>medp2012214@med.uoc.gr</email> (M.I.K.); <email>e.papadaki@uoc.gr</email> (H.A.P.)</aff><aff id="af2-hematolrep-17-00025"><label>2</label>Department of Pathology, School of Medicine, University of Crete, 71500 Heraklion, Greece; <email>kokkinakhsgianniskims@gmail.com</email></aff><aff id="af3-hematolrep-17-00025"><label>3</label>Department of Medical Imaging, University General Hospital of Heraklion, 71500 Heraklion, Greece; <email>markastella@yahoo.gr</email></aff><aff id="af4-hematolrep-17-00025"><label>4</label>Department of Hemopathology, Evangelismos General Hospital, 11521 Athens, Greece; <email>cmasaout@med.uoa.gr</email></aff><aff id="af5-hematolrep-17-00025"><label>5</label>Internal Medicine-Hematology, University of Patras Medical School, 26500 Rion, Greece; <email>esolomou@upatras.gr</email></aff><aff id="af6-hematolrep-17-00025"><label>6</label>Department of Intensive Care Medicine, University General Hospital of Heraklion, 71500 Heraklion, Greece; <email>medp2011875@med.uoc.gr</email> (I.P.); <email>nxirouchaki@pagni.gr</email> (N.X.)</aff><aff id="af7-hematolrep-17-00025"><label>7</label>Department of Hematology, Aghios Georgios Hospital, 73300 Chania, Greece; <email>aimatologiki@chaniahospital.gr</email></aff><author-notes><corresp id="c1-hematolrep-17-00025"><label>*</label>Correspondence: <email>xpontik@uoc.gr</email>; Tel.: +30-2810392781</corresp><fn id="fn1-hematolrep-17-00025"><label>&#x02020;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>06</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2025</year></pub-date><volume>17</volume><issue>3</issue><elocation-id>25</elocation-id><history><date date-type="received"><day>26</day><month>3</month><year>2025</year></date><date date-type="rev-recd"><day>24</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>28</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Background: Severe aplastic anemia (SAA) is an uncommon life-threatening disorder characterized by hypocellular bone marrow and pancytopenia. It is typically associated with immune-mediated mechanisms, requiring immunosuppressive therapy (IST) or hematopoietic stem cell transplantation (HSCT). Infections, especially invasive fungal infections such as mucormycosis and aspergillosis, constitute principal causes of morbidity and mortality in patients with SAA. Genetic predispositions, including perforin (PRF1) polymorphisms, may further complicate disease outcomes by impairing immune function. Case report: We describe a case of a 36-year-old female patient diagnosed with SAA, for whom IST was considered, due to the unavailability of a matched sibling donor for HSCT. The patient presented with a feverish condition and deep neck space abscesses were revealed by imaging, caused by invasive aspergillosis. To prioritize infection control, IST was postponed and antifungal therapy with abscess drainage was initiated. However, aspergillosis progressed, despite aggressive and prompt treatment, and ultimately resulted in sepsis, multiorgan failure, and death. In addition, mucormycosis was confirmed post-mortem. Two heterozygous <italic toggle="yes">PRF1</italic> polymorphisms (c.272C&#x0003e;T and c.900C&#x0003e;T), were identified by genetic testing, which may have contributed to immune dysregulation and fungal dissemination. Conclusions: The complex interplay between managing SAA and addressing invasive fungal infections, which remain a leading cause of mortality in immunocompromised patients, is highlighted in this case. The latter emphasizes the importance of prompt diagnosis and targeted treatment to alleviate infection-related complications while maintaining care continuity for the hematologic disorder. The detection of <italic toggle="yes">PRF1</italic> polymorphisms raises questions about their implication in immune regulation and disease trajectory, emphasizing the need for further research in this field.</p></abstract><kwd-group><kwd>severe aplastic anemia</kwd><kwd>perforin gene mutation</kwd><kwd>immunosuppressive therapy</kwd><kwd>aspergillosis</kwd><kwd>mucormycosis</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-hematolrep-17-00025"><title>1. Introduction</title><p>Aplastic anemia (AA) is a rare disorder characterized by pancytopenia and a hypocellular bone marrow (BM) in the absence of significant dysplasia, abnormal infiltrate or marrow fibrosis [<xref rid="B1-hematolrep-17-00025" ref-type="bibr">1</xref>,<xref rid="B2-hematolrep-17-00025" ref-type="bibr">2</xref>]. In approximately 70% of cases, AA is acquired, with the majority being idiopathic [<xref rid="B1-hematolrep-17-00025" ref-type="bibr">1</xref>,<xref rid="B2-hematolrep-17-00025" ref-type="bibr">2</xref>,<xref rid="B3-hematolrep-17-00025" ref-type="bibr">3</xref>,<xref rid="B4-hematolrep-17-00025" ref-type="bibr">4</xref>], while the remaining cases are attributed to inherited BM failure syndrome [<xref rid="B1-hematolrep-17-00025" ref-type="bibr">1</xref>,<xref rid="B2-hematolrep-17-00025" ref-type="bibr">2</xref>,<xref rid="B4-hematolrep-17-00025" ref-type="bibr">4</xref>]. Diagnostic features of AA include the presence of at least two of the following: hemoglobin (Hgb) &#x0003c; 10 g/dL, platelet (PLT) count &#x0003c; 50 &#x000d7; 109/L, or neutrophil count &#x0003c; 1.5 &#x000d7; 109/L [<xref rid="B2-hematolrep-17-00025" ref-type="bibr">2</xref>,<xref rid="B5-hematolrep-17-00025" ref-type="bibr">5</xref>].</p><p>In terms of risk stratification, AA can be classified into three categories [<xref rid="B2-hematolrep-17-00025" ref-type="bibr">2</xref>,<xref rid="B5-hematolrep-17-00025" ref-type="bibr">5</xref>,<xref rid="B6-hematolrep-17-00025" ref-type="bibr">6</xref>,<xref rid="B7-hematolrep-17-00025" ref-type="bibr">7</xref>]: (1) Severe AA (SAA): characterized by marrow cellularity below 25% and at least two of the following: (a) neutrophil count below 0.5 &#x000d7; 10&#x02079;/L, (b) PLT count below 20 &#x000d7; 10&#x02079;/L, or (c) reticulocyte count below 60 &#x000d7; 10&#x02079;/L (using an automated reticulocyte count). (2) Very severe AA (VSAA): defined similarly to SAA, but with a neutrophil count below 0.2 &#x000d7; 10&#x02079;/L. (3) Non-severe AA (NSAA): refers to AA cases that do not meet the criteria for SAA or VSAA [<xref rid="B2-hematolrep-17-00025" ref-type="bibr">2</xref>,<xref rid="B5-hematolrep-17-00025" ref-type="bibr">5</xref>,<xref rid="B6-hematolrep-17-00025" ref-type="bibr">6</xref>,<xref rid="B7-hematolrep-17-00025" ref-type="bibr">7</xref>].</p><p>As the majority of acquired aplastic anemia cases, particularly those that are severe and acute, are believed to be immune-mediated, the conventional treatment for SAA/VSAA includes IST with antithymocyte globulin (ATG), cyclosporine (CSA) and eltrombopag [<xref rid="B2-hematolrep-17-00025" ref-type="bibr">2</xref>,<xref rid="B7-hematolrep-17-00025" ref-type="bibr">7</xref>,<xref rid="B8-hematolrep-17-00025" ref-type="bibr">8</xref>]. Hematopoietic cell transplantation from a matched related donor is also considered a standard curative approach in eligible patients [<xref rid="B2-hematolrep-17-00025" ref-type="bibr">2</xref>,<xref rid="B7-hematolrep-17-00025" ref-type="bibr">7</xref>,<xref rid="B8-hematolrep-17-00025" ref-type="bibr">8</xref>]. Emerging therapeutic approaches, although not routinely used in the upfront setting, include hematopoietic stem cell transplantation from matched unrelated donors and haploidentical donors [<xref rid="B2-hematolrep-17-00025" ref-type="bibr">2</xref>,<xref rid="B7-hematolrep-17-00025" ref-type="bibr">7</xref>,<xref rid="B8-hematolrep-17-00025" ref-type="bibr">8</xref>]. In selected cases of NSAA, less intensive immunosuppressive treatment consisting of ATG and CSA, may be employed [<xref rid="B2-hematolrep-17-00025" ref-type="bibr">2</xref>,<xref rid="B7-hematolrep-17-00025" ref-type="bibr">7</xref>,<xref rid="B8-hematolrep-17-00025" ref-type="bibr">8</xref>].</p><p>Infections are the leading cause of death in AA [<xref rid="B9-hematolrep-17-00025" ref-type="bibr">9</xref>,<xref rid="B10-hematolrep-17-00025" ref-type="bibr">10</xref>,<xref rid="B11-hematolrep-17-00025" ref-type="bibr">11</xref>,<xref rid="B12-hematolrep-17-00025" ref-type="bibr">12</xref>], where neutropenia&#x02014;often prolonged&#x02014;significantly increases the risk of invasive fungal infections and bacterial sepsis. Invasive fungal infections, particularly those caused by <italic toggle="yes">Aspergillus</italic> species, are a primary cause of mortality in AA patients [<xref rid="B9-hematolrep-17-00025" ref-type="bibr">9</xref>,<xref rid="B10-hematolrep-17-00025" ref-type="bibr">10</xref>,<xref rid="B13-hematolrep-17-00025" ref-type="bibr">13</xref>,<xref rid="B14-hematolrep-17-00025" ref-type="bibr">14</xref>]. Interestingly, <italic toggle="yes">Zygomycetes</italic> (<italic toggle="yes">Mucor</italic>, <italic toggle="yes">Rhizopus</italic> spp.), often clinically reported as &#x0201c;mucormycosis&#x0201d;, are the second leading cause of invasive fungal infections in AA [<xref rid="B10-hematolrep-17-00025" ref-type="bibr">10</xref>,<xref rid="B15-hematolrep-17-00025" ref-type="bibr">15</xref>,<xref rid="B16-hematolrep-17-00025" ref-type="bibr">16</xref>,<xref rid="B17-hematolrep-17-00025" ref-type="bibr">17</xref>].</p><p>We report a patient with SAA in whom genetic screening to exclude an inherited BM failure (IBFM) syndrome revealed polymorphisms in <italic toggle="yes">PRF1</italic>, a gene encoding perforin, previously associated with adverse prognosis [<xref rid="B18-hematolrep-17-00025" ref-type="bibr">18</xref>]. The patient&#x02019;s course was complicated by aspergillosis and mucormycosis, resulting in death on day 51 of admission.</p></sec><sec id="sec2-hematolrep-17-00025"><title>2. Case Presentation</title><p>A 36-year-old Greek female patient, mother of two, with no significant medical or family history presented in the emergency department of a regional Greek hospital due to bruising on the trunk and the extremities. She was not taking any medication and had no history of recent infections. Nevertheless, she reported inhaling fumes from floor-cleaning solutions one day prior to her presentation. On examination, the patient had normal vital signs and was alert. Ecchymoses and petechiae were noted on the face, trunk and extremities, as well as soft palatal purpura. There was no peripheral lymphadenopathy, hepatomegaly or splenomegaly. Laboratory tests revealed a white blood cell count of 4100/&#x003bc;L (4000&#x02013;10,000/&#x003bc;L), an absolute neutrophil count of 3170/&#x003bc;L (1750&#x02013;8500/&#x003bc;L), and an absolute lymphocyte count of 800/&#x003bc;L (1500&#x02013;4000/&#x003bc;L). Hgb was 12 g/dL (11.5&#x02013;15.5 g/dL) with a reticulocyte count of 10 &#x000d7; 10<sup>9</sup>/L. PLT count was 10,000/&#x003bc;L (150,000/&#x003bc;L&#x02013;450,000/&#x003bc;L). Examination of the peripheral blood smear confirmed the profound decrease in PLT numbers and showed a slight increase in PLT size, while both white and red blood cells appeared normal. There were no signs of hemolysis, and coagulation parameters, glucose levels, renal and liver function tests were all within normal limits. Serum immunoglobulin levels and thyroid function tests were also within the normal range. Serologic testing for Hepatitis B virus, Hepatitis C virus, Human Immunodeficiency Virus, Parvovirus B19, Herpes Simplex Virus, Varicella-Zoster Virus, Cytomegalovirus, and Epstein&#x02013;Barr Virus was negative. Antinuclear antibody screening and the direct Coombs test were also negative. Based on these findings, a diagnosis of immune thrombocytopenia (ITP) was made, and the patient was treated with intravenous immunoglobulin and corticosteroids. On day +4, not only did PLT counts fail to increase, but the Hgb levels also declined (7.2 gr/dL) and the absolute neutrophil count (1000/&#x003bc;L) decreased. Bone marrow aspiration demonstrated marked hypocellularity, which was further confirmed by bone marrow trephine biopsy. The biopsy (<xref rid="hematolrep-17-00025-f001" ref-type="fig">Figure 1</xref>A&#x02013;C) revealed a predominant population of T lymphocytes, which were scarce overall, with rare Granzyme-B-expressing cells, as well as a few polyclonal plasma cells, macrophages and mast cells. Rare granulocytic cells were also observed, while megakaryocytic and erythroid lineages were absent. CD34 immunohistochemistry was negative, and stromal edema was present. These findings raised the suspicion of SAA (<xref rid="hematolrep-17-00025-f002" ref-type="fig">Figure 2</xref>). <italic toggle="yes">PRF1</italic> sequencing revealed two heterozygous polymorphisms: c.272C&#x0003e;T (p.A91V; rs35947132) and c.900C&#x0003e;T (p.H300H; rs885822). According to ClinVar (RCV000547554.3; accessed 24 April 2025), the <italic toggle="yes">PRF1</italic> p.A91V variant exhibits inconsistent pathogenicity interpretations, with submissions classifying it from benign to unknown significance. The <italic toggle="yes">PRF1</italic> p.H300H variant is a synonymous alteration that is uniformly categorized as benign in ClinVar.</p><p>From day +7 until day +37, the patient continued inpatient care at the referring regional hospital, receiving supportive therapy consisting of PLT and red blood cell transfusions, epoetin zeta 40,000 IU/week, G-CSF 300 mcg o.d. and eltrombopag 150 mg o.d (<xref rid="hematolrep-17-00025-f002" ref-type="fig">Figure 2</xref>). According to international guidelines, as the patient was medically fit and under 40 years of age, she should have proceeded directly to hematopoietic stem cell transplantation if a histocompatibility leukocyte antigen (HLA) matched sibling donor had been identified. However, HLA typing failed to identify a suitable related donor and since the search for an unrelated donor was expected to take at least 8 weeks, the patient was transferred to the Hematology Department of a tertiary Greek hospital for immunosuppressive treatment with ATG and CSA.</p><p>On admission (day +37), the patient was febrile and ill-appearing (<xref rid="hematolrep-17-00025-f002" ref-type="fig">Figure 2</xref>). She complained of a sore throat and difficulty in swallowing and was noted to have a &#x0201c;hot potato&#x0201d; voice. A deep-neck space infection was suspected and urgent ear&#x02013;nose&#x02013;throat (ENT) consultation and imaging studies were ordered. Head CT scan was normal, whereas neck CT scan revealed both nasopharyngeal and retropharyngeal abscesses, with the latter extending into the deep neck spaces (<xref rid="hematolrep-17-00025-f003" ref-type="fig">Figure 3</xref>A&#x02013;D). A chest CT scan demonstrated consolidations in the left upper lobe and right middle lobe (<xref rid="hematolrep-17-00025-f003" ref-type="fig">Figure 3</xref>E,F), centrilobular nodules with tree-in-bud pattern (<xref rid="hematolrep-17-00025-f003" ref-type="fig">Figure 3</xref>G), along with few predominantly peripheral nodules, some of them with a ground-glass halo (<xref rid="hematolrep-17-00025-f003" ref-type="fig">Figure 3</xref>H,I).</p><p>Urgent abscess drainage, on day +37, revealed a loose formation with central necrosis, whereas pharyngeal puncture at the level of the epiglottis, to detect any residual abscess tissue, was negative. The patient was transferred to the Intensive Care Unit where she remained intubated under mechanical ventilation. She was febrile and hemodynamically unstable and received empiric broad-spectrum antibiotic therapy consisting of meropenem 2 gr t.i.d. and daptomycin 500 mg o.d., as well as corticosteroids for sepsis. The histopathologic results (rapid tissue biopsy) showed the presence of fungal hyphae (<xref rid="hematolrep-17-00025-f004" ref-type="fig">Figure 4</xref>) suggestive of <italic toggle="yes">Aspergillus</italic> spp. and the positive result of the Aspergillus-specific PCR assay in the nasophaygeal samples further supported this diagnosis (<xref rid="hematolrep-17-00025-f002" ref-type="fig">Figure 2</xref>). Antifungal therapy with isavuconazole 200 mg t.i.d. plus micafungin 100 mg o.d. was initiated on day +38.</p><p>As the fever persisted, and the general condition of the patient progressively deteriorated, antibiotic escalation was performed on day +39: meropenem was discontinued and ceftazidime tazobactam 2.5 gr t.i.d. and colistin 4.500.000 units b.i.d. were added. Of note, regular endoscopic examinations by the otolaryngologists failed to demonstrate any new signs of infection. On day +42, the patient developed lower quadrant tenderness, and bedside ultrasound revealed a large splenic infarct, which was confirmed by an abdominal CT scan. Because of this finding and as eltrombopag is rarely associated with thromboembolism [<xref rid="B19-hematolrep-17-00025" ref-type="bibr">19</xref>], its administration was discontinued and the patient was maintained on PLT transfusions. A neck CT scan demonstrated extension of the fluid collection at the site of the previously treated surgical abscess into the nasal cavity and paranasal sinuses, while the retropharyngeal fluid showed a mild reduction in its craniocaudal diameter. Disease progression was also observed in a chest CT scan, including worsening consolidation in the left upper lobe, the appearance of a new smaller consolidation in the right upper lobe, and increased ground-glass opacities and solid nodules scattered throughout both lungs. These findings were not specific but could be due to a fungal etiology. Indeed, <italic toggle="yes">Aspergillus</italic>-specific PCR assay from the bronchoalveolar lavage on day +43 confirmed the diagnosis of invasive pulmonary aspergillosis (<xref rid="hematolrep-17-00025-f002" ref-type="fig">Figure 2</xref>).</p><p>Due to the high risk of hemorrhage, further surgical intervention was deemed inappropriate. The patient was instead maintained on antibiotic treatment and underwent regular transnasal drainage of the nasopharynx. Immunomodulatory treatment as salvage therapy for the underlying aplastic anemia was considered but ultimately rejected due to the presence of active infection. On day +45, a lung ultrasound was performed to investigate worsening respiratory failure, which confirmed progression of findings from the previous CT scan. Additionally, the patient was diagnosed with acute kidney injury and acute coronary syndrome. Cardiac ultrasound showed significantly reduced left ventricular contractility with signs of diffuse hypokinesia, most likely diagnostic of septic cardiomyopathy. Despite intensive management, the patient&#x02019;s condition deteriorated rapidly over the next few hours, and she succumbed to sepsis and multiorgan dysfunction on day +46 (<xref rid="hematolrep-17-00025-f002" ref-type="fig">Figure 2</xref>). Notably, nasopharyngeal cultures returned for <italic toggle="yes">Mucor</italic> spp. five days after her death, suggesting aspergillosis and mucormycosis coinfection (<xref rid="hematolrep-17-00025-f002" ref-type="fig">Figure 2</xref>).</p></sec><sec sec-type="discussion" id="sec3-hematolrep-17-00025"><title>3. Discussion</title><p>We describe a case of a 36-year-old female patient who was diagnosed with SAA in a regional hospital of Crete. As the patient was medically fit and younger than 40 years old, allogeneic HSCT from a matched sibling donor should have been performed upfront, according to current practice [<xref rid="B2-hematolrep-17-00025" ref-type="bibr">2</xref>,<xref rid="B20-hematolrep-17-00025" ref-type="bibr">20</xref>,<xref rid="B21-hematolrep-17-00025" ref-type="bibr">21</xref>] Yet, HLA typing did not identify a suitable related donor. In light of recent studies and evolving guidelines, upfront matched unrelated donor (MUD) HSCT was also considered as a viable option [<xref rid="B2-hematolrep-17-00025" ref-type="bibr">2</xref>,<xref rid="B7-hematolrep-17-00025" ref-type="bibr">7</xref>,<xref rid="B22-hematolrep-17-00025" ref-type="bibr">22</xref>]. However, this option requires that a suitable donor be readily available [<xref rid="B2-hematolrep-17-00025" ref-type="bibr">2</xref>,<xref rid="B7-hematolrep-17-00025" ref-type="bibr">7</xref>,<xref rid="B22-hematolrep-17-00025" ref-type="bibr">22</xref>], which was not the case. Indeed, the procedure of selecting an appropriate unrelated donor and completing the requisite preliminary stages for transplantation was expected to take a minimum of eight to twelve weeks. Due to the urgency of treatment initiation, the patient was transported to the Hematology Department of a tertiary hospital to begin immunosuppressive medication with ATG and CSA with the addition of eltrombopag, based on the existing literature [<xref rid="B2-hematolrep-17-00025" ref-type="bibr">2</xref>,<xref rid="B23-hematolrep-17-00025" ref-type="bibr">23</xref>]. On admission, though, the patient presented with fever and appeared clinically unwell. Deep neck space abscesses were identified and attributed to invasive aspergillosis. This prompted urgent drainage and the initiation of fungal and antibiotic therapy. Immunosuppressive treatment was deferred in order to control infection and achieve defervescence [<xref rid="B2-hematolrep-17-00025" ref-type="bibr">2</xref>,<xref rid="B20-hematolrep-17-00025" ref-type="bibr">20</xref>]</p><p>Infections are the leading cause of mortality in individuals with AA [<xref rid="B9-hematolrep-17-00025" ref-type="bibr">9</xref>,<xref rid="B10-hematolrep-17-00025" ref-type="bibr">10</xref>,<xref rid="B11-hematolrep-17-00025" ref-type="bibr">11</xref>,<xref rid="B12-hematolrep-17-00025" ref-type="bibr">12</xref>]. A retrospective study of patients with aplastic anemia (AA) admitted to the National Institutes of Health between 1978 and 1990 reported that 62% of patient deaths were attributed to infections, with invasive fungal infections caused by <italic toggle="yes">Aspergillus</italic> spp. and <italic toggle="yes">Candida</italic> spp. accounting for 50% of these infection-related death [<xref rid="B9-hematolrep-17-00025" ref-type="bibr">9</xref>]. Similarly, a study conducted at the MD Anderson Cancer Center reported that between 1994 and 2000, 42% of AA-related deaths were attributed to fungal infections, predominantly mold infections [<xref rid="B13-hematolrep-17-00025" ref-type="bibr">13</xref>]. In contrast, a more recent retrospective study from Thailand found that between 2010 and 2015, only 16.9% of patients with AA died from fungal infections [<xref rid="B24-hematolrep-17-00025" ref-type="bibr">24</xref>]. This decrease in fungal-infection-related mortality is consistent with the observed reduction in the prevalence of these infections in patients with AA after the year 2000 [<xref rid="B10-hematolrep-17-00025" ref-type="bibr">10</xref>]. Across all these studies, the neutropenia associated with AA, particularly when severe and prolonged, was documented to significantly increase the risk of infections [<xref rid="B9-hematolrep-17-00025" ref-type="bibr">9</xref>,<xref rid="B10-hematolrep-17-00025" ref-type="bibr">10</xref>,<xref rid="B11-hematolrep-17-00025" ref-type="bibr">11</xref>,<xref rid="B12-hematolrep-17-00025" ref-type="bibr">12</xref>,<xref rid="B13-hematolrep-17-00025" ref-type="bibr">13</xref>].</p><p>As invasive aspergillosis and mucormycosis are life-threatening fungal infections in immunocompromised patients [<xref rid="B25-hematolrep-17-00025" ref-type="bibr">25</xref>,<xref rid="B26-hematolrep-17-00025" ref-type="bibr">26</xref>], early diagnosis is crucial for improving prognosis. However, this remains a significant challenge, requiring a high index of suspicion, thorough assessment of host risk factors, and prompt evaluation of clinical manifestations, which are often nonspecific [<xref rid="B25-hematolrep-17-00025" ref-type="bibr">25</xref>,<xref rid="B26-hematolrep-17-00025" ref-type="bibr">26</xref>]. In the case reported here, the patient&#x02019;s neutropenia&#x02014;a key predisposing factor for invasive fungal infections [<xref rid="B27-hematolrep-17-00025" ref-type="bibr">27</xref>,<xref rid="B28-hematolrep-17-00025" ref-type="bibr">28</xref>]&#x02014;heightened our vigilance when the possibility of a deep-neck space infection was considered. As Galactomannan testing&#x02014;a serum assay for detecting a polysaccharide cell wall component of <italic toggle="yes">Aspergillus</italic> spp. [<xref rid="B29-hematolrep-17-00025" ref-type="bibr">29</xref>]&#x02014;was not available at the time of hospitalization, the diagnosis of invasive aspergillosis was established through histopathological examination. Specimens from the necrotic formation removed from the nasopharynx revealed typical dichotomous and septate hyphae consistent with <italic toggle="yes">Aspergillus</italic> spp. [<xref rid="B30-hematolrep-17-00025" ref-type="bibr">30</xref>]. The diagnosis was further supported by a positive <italic toggle="yes">Aspergillus</italic> PCR test from the nasopharyngeal samples, while PCR testing of BAL provided evidence for invasive pulmonary aspergillosis. Interestingly, cultures from both the nasopharyngeal abscess and BAL were negative for <italic toggle="yes">Aspergillus</italic> spp., reflecting the low sensitivity of this diagnostic method [<xref rid="B29-hematolrep-17-00025" ref-type="bibr">29</xref>]. However, tissue cultures from the nasopharynx tested positive for <italic toggle="yes">Mucor</italic> spp., five days after the patient&#x02019;s death, despite the absence of identifiable hyphae in the histopathological examination. Pulmonary imaging studies were non-specific. This highlights the importance of employing multiple diagnostic approaches when assessing a patient for invasive fungal infection.</p><p>The treatment of invasive aspergillosis in our patient consisted of drainage of the nasopharyngeal abscess and combination antifungal therapy. Unfortunately, the infection progressed at the nasopharynx and paranasal sinuses and in the lungs, as evidenced by the respective imaging studies 6 days later. Surgical debridement, as adjunctive therapy for Aspergillus rhinosinusitis [<xref rid="B31-hematolrep-17-00025" ref-type="bibr">31</xref>,<xref rid="B32-hematolrep-17-00025" ref-type="bibr">32</xref>], was considered but ultimately rejected due to concerns regarding surgical complications, particularly hemorrhage, given the patient&#x02019;s severe thrombocytopenia.</p><p>AA is a diagnosis of exclusion that requires ruling out other causes of pancytopenia with hypocellular BM, including &#x00399;BFM, especially in patients aged &#x0003c; 40 or with a positive family history and suggestive physical features [<xref rid="B2-hematolrep-17-00025" ref-type="bibr">2</xref>,<xref rid="B4-hematolrep-17-00025" ref-type="bibr">4</xref>]. Within this context, AA must be distinguished from hemophagocytic lymphohistiocytosis (HLH) [<xref rid="B18-hematolrep-17-00025" ref-type="bibr">18</xref>,<xref rid="B33-hematolrep-17-00025" ref-type="bibr">33</xref>].</p><p>HLH is a rare, rapidly progressive and potentially life-threatening syndrome characterized by extreme immune system activation that can present with pancytopenia and usually manifests as a febrile disorder associated with multiorgan dysfunction [<xref rid="B34-hematolrep-17-00025" ref-type="bibr">34</xref>,<xref rid="B35-hematolrep-17-00025" ref-type="bibr">35</xref>]. HLH is classified as either primary (familial), due to inherited genetic mutations, or secondary, triggered by an abnormal immune response to infection, malignancy, or autoimmune disease [<xref rid="B35-hematolrep-17-00025" ref-type="bibr">35</xref>].</p><p>The etiological association of mutations of the PRF1 gene with familial HLH has been well established [<xref rid="B34-hematolrep-17-00025" ref-type="bibr">34</xref>,<xref rid="B35-hematolrep-17-00025" ref-type="bibr">35</xref>]. Perforin, a protein stored in the secretory granules in CD8+ T cells and natural killer (NK) cells, is critically implicated in their cytotoxic activity [<xref rid="B36-hematolrep-17-00025" ref-type="bibr">36</xref>]. Upon activation, these lymphocytes release perforin, which subsequently forms pores in the membrane of the target cell, resulting in osmotic lysis. In addition, perforin facilitates the delivery of the proapoptotic serine protease granzyme B, also stored in cytotoxic lymphocyte granules, into the target cell triggering apoptosis [<xref rid="B36-hematolrep-17-00025" ref-type="bibr">36</xref>,<xref rid="B37-hematolrep-17-00025" ref-type="bibr">37</xref>].</p><p>Germline genetic testing in our patient revealed the presence of two heterozygous <italic toggle="yes">PRF1</italic> polymorphisms: c.272C&#x0003e;T (p.A91V; rs35947132) and c.900C&#x0003e;T (p.H300H; rs885822). The presence of PRF1 genetic alterations in AA patients has been previously documented in two studies [<xref rid="B18-hematolrep-17-00025" ref-type="bibr">18</xref>,<xref rid="B38-hematolrep-17-00025" ref-type="bibr">38</xref>]. In the study by Solomou et al., <italic toggle="yes">PRF1</italic> variants were identified in 5 out of 75 AA patients [<xref rid="B18-hematolrep-17-00025" ref-type="bibr">18</xref>]. Three of these patients harbored the A91V and H300H polymorphisms and two of them exhibited hemophagocytosis in the bone marrow but did not display the other typical features of HLH. Interestingly, no hemophagocytosis could be detected in our patient despite the presence of macrophages in the BM. It has been postulated that <italic toggle="yes">PRF1</italic> variants may be associated with a more severe form of AA, as patients harboring these variants either failed to respond to immunosuppressive therapy or demonstrated only a partial response [<xref rid="B18-hematolrep-17-00025" ref-type="bibr">18</xref>]. Another study by Rafati et al. [<xref rid="B38-hematolrep-17-00025" ref-type="bibr">38</xref>] employed whole-exome sequencing to assess the frequency of gene variants in 14 HLH-associated genes in a cohort of 684 patients with SAA who had undergone unrelated donor HSCT. In that study, the <italic toggle="yes">PRF1</italic> variant c.272C&#x0003e;T (p.A91V; rs35947132) was detected in 8.5% (58 of 684) of SAA patients. Yet, in contrast to the findings of Solomou et al. [<xref rid="B18-hematolrep-17-00025" ref-type="bibr">18</xref>], it was not associated with a worse post-HSCT survival.</p><p>Pre-clinical studies have shown that perforin is crucial for primary immunity against specific fungal infections. For instance, mice lacking perforin demonstrate heightened mortality and an elevated fungal load after infection with Histoplasma capsulatum [<xref rid="B39-hematolrep-17-00025" ref-type="bibr">39</xref>]. Furthermore, previous reports have demonstrated that perforin plays a critical role in natural killer (NK)-cell-mediated antifungal activity against invasive mold infections [<xref rid="B40-hematolrep-17-00025" ref-type="bibr">40</xref>]. In particular, in vitro evidence demonstrates that pretreatment of human NK cells with concanamycin A, which accelerates perforin degradation, significantly reduces hyphal damage caused by <italic toggle="yes">Aspergillus fumigatus</italic> and <italic toggle="yes">Rhizopus oryzae</italic>, whereas exposure to purified perforin enhances hyphal killing [<xref rid="B41-hematolrep-17-00025" ref-type="bibr">41</xref>,<xref rid="B42-hematolrep-17-00025" ref-type="bibr">42</xref>].</p><p>Patients with AA carrying PRF1 genetic alterations have been reported to exhibit low or absent perforin levels and significantly impaired NK cell cytotoxicity [<xref rid="B18-hematolrep-17-00025" ref-type="bibr">18</xref>]. In addition, heterozygous healthy carriers of the PRF1 p.A91V variant (A91V/+) have been shown to exhibit at least a 35% reduction in NK cytotoxicity compared with wild-type individuals [<xref rid="B43-hematolrep-17-00025" ref-type="bibr">43</xref>]. Our patient was heterozygous for the PRF1 c.272C&#x0003e;T (p.Ala91Val; rs35947132) variant, whose pathogenicity classification in ClinVar ranges from benign to uncertain significance. She also harbored the synonymous PRF1 c.900C&#x0003e;T (p.H300H) variant, which is deemed benign. We recognize that individuals with SAA are inherently at high risk for invasive fungal infections and may succumb to them regardless of underlying genetic predisposition [<xref rid="B9-hematolrep-17-00025" ref-type="bibr">9</xref>,<xref rid="B10-hematolrep-17-00025" ref-type="bibr">10</xref>,<xref rid="B11-hematolrep-17-00025" ref-type="bibr">11</xref>,<xref rid="B12-hematolrep-17-00025" ref-type="bibr">12</xref>]. However, based on previous reports linking the p.A91V variant with reduced NK cell cytotoxicity [<xref rid="B40-hematolrep-17-00025" ref-type="bibr">40</xref>,<xref rid="B43-hematolrep-17-00025" ref-type="bibr">43</xref>], we hypothesize that its presence may have impaired antifungal immune responses in this patient, potentially increasing her susceptibility to the spread of invasive aspergillosis and its lethal consequences. This interpretation remains controversial, especially as a large study could not establish a definitive disease association with this variant [<xref rid="B44-hematolrep-17-00025" ref-type="bibr">44</xref>]. Further research is warranted to shed light on the clinical relevance of the p.A19V variant in the context of infection susceptibility</p></sec><sec sec-type="conclusions" id="sec4-hematolrep-17-00025"><title>4. Conclusions</title><p>We present the case of a 36-year-old female patient diagnosed with SAA who was transferred to the Hematology Department of the University General Hospital of Heraklion (PAGNI) for IST due to the absence of a matched sibling donor for allogeneic HSCT. The patient presented with fever, and deep neck space abscesses were identified, attributed to invasive aspergillosis. IST was postponed to treat the infection, which was further complicated by mucormycosis. Aspergillosis infection progressed and involved the lungs and paranasal sinuses, ultimately leading to the patient&#x02019;s death, despite the prompt initiation of surgical drainage of the abscess and antifungal therapy.</p><p>This case highlights the significant difficulties in the management of SAA, especially in the presence of life-threatening fungal infections, which necessitate balancing the need for IST with infection control. It also underscores the need for prompt and aggressive diagnostic and therapeutic modalities to manage infections in immunocompromised patients. Finally, the detection of <italic toggle="yes">PRF1</italic> polymorphisms in this patient raises important questions about their potential impact on immune dysregulation and disease progression, emphasizing the necessity for further research in this area.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, C.G.P., E.S. and H.A.P.; Writing&#x02014;Original Draft Preparation, M.I.K., I.K., S.M., C.M. and C.G.P.; Writing&#x02014;Review and Editing, M.I.K., I.K., S.M., C.M., E.S., I.P., N.X., I.L., H.A.P. and C.G.P.; Data Acquisition, Analysis and Interpretation, M.I.K., I.K., S.M., C.M., E.S., I.P., N.X., I.L., H.A.P. and C.G.P.; Supervision C.G.P. and H.A.P. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>This study was conducted in accordance with the Declaration of Helsinki. Ethical review and approval were waived for this study in accordance with the policy of the Ethics Committee of the University General Hospital of Heraklion, which states that retrospective analyses of patient data for case reports do not require approval and are therefore eligible for a waiver.</p></notes><notes><title>Informed Consent Statement</title><p>Informed consent was obtained from the patients&#x02019; next of kin. Written informed consent has been obtained from the patient&#x02019;s next of kin to publish this paper.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The authors confirm that the data supporting this study are available in this article.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><glossary><title>Abbreviations</title><p>The following abbreviations are used in this manuscript:
<array><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">AA</td><td align="left" valign="middle" rowspan="1" colspan="1">Aplastic Anemia</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ATG</td><td align="left" valign="middle" rowspan="1" colspan="1">Antithymocyte Globulin</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BM</td><td align="left" valign="middle" rowspan="1" colspan="1">Bone Marrow</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BMF</td><td align="left" valign="middle" rowspan="1" colspan="1">Bone Marrow Failure</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CSA</td><td align="left" valign="middle" rowspan="1" colspan="1">Cyclosporine</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ENT</td><td align="left" valign="middle" rowspan="1" colspan="1">Ear-Nose-Throat</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">GCSF</td><td align="left" valign="middle" rowspan="1" colspan="1">Granulocyte Colony-Stimulating Factor</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Hgb</td><td align="left" valign="middle" rowspan="1" colspan="1">Hemoglobin</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HLA</td><td align="left" valign="middle" rowspan="1" colspan="1">Histocompatibility Leukocyte Antigen</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HLH</td><td align="left" valign="middle" rowspan="1" colspan="1">Hemophagocytic Lymphohistiocytosis</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HSCT</td><td align="left" valign="middle" rowspan="1" colspan="1">Hematopoietic Stem Cell Transplantation</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IBFM</td><td align="left" valign="middle" rowspan="1" colspan="1">Inherited Bone Marrow Failure</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IST</td><td align="left" valign="middle" rowspan="1" colspan="1">Immunosuppressive Therapy</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ITP</td><td align="left" valign="middle" rowspan="1" colspan="1">Immune Thrombocytopenia</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NK</td><td align="left" valign="middle" rowspan="1" colspan="1">Natural Killer</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NSAA</td><td align="left" valign="middle" rowspan="1" colspan="1">Non-Severe Aplastic Anemia</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PCR</td><td align="left" valign="middle" rowspan="1" colspan="1">Polymerase Chain Reaction</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PLT</td><td align="left" valign="middle" rowspan="1" colspan="1">Platelet</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PRF1</td><td align="left" valign="middle" rowspan="1" colspan="1">Perforin</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SAA</td><td align="left" valign="middle" rowspan="1" colspan="1">Severe Aplastic Anemia</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">VSAA</td><td align="left" valign="middle" rowspan="1" colspan="1">Very Severe Aplastic Anemia</td></tr></tbody></array></p></glossary><ref-list><title>References</title><ref id="B1-hematolrep-17-00025"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Young</surname><given-names>N.S.</given-names></name>
</person-group><article-title>Aplastic Anemia</article-title><source>N. Engl. J. Med.</source><year>2018</year><volume>379</volume><fpage>1643</fpage><lpage>1656</lpage><pub-id pub-id-type="doi">10.1056/NEJMra1413485</pub-id><pub-id pub-id-type="pmid">30354958</pub-id>
</element-citation></ref><ref id="B2-hematolrep-17-00025"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kulasekararaj</surname><given-names>A.</given-names></name>
<name><surname>Cavenagh</surname><given-names>J.</given-names></name>
<name><surname>Dokal</surname><given-names>I.</given-names></name>
<name><surname>Foukaneli</surname><given-names>T.</given-names></name>
<name><surname>Gandhi</surname><given-names>S.</given-names></name>
<name><surname>Garg</surname><given-names>M.</given-names></name>
<name><surname>Griffin</surname><given-names>M.</given-names></name>
<name><surname>Hillmen</surname><given-names>P.</given-names></name>
<name><surname>Ireland</surname><given-names>R.</given-names></name>
<name><surname>Killick</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology Guideline</article-title><source>Br. J. Haematol.</source><year>2024</year><volume>204</volume><fpage>784</fpage><lpage>804</lpage><pub-id pub-id-type="doi">10.1111/bjh.19236</pub-id><pub-id pub-id-type="pmid">38247114</pub-id>
</element-citation></ref><ref id="B3-hematolrep-17-00025"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ahmed</surname><given-names>P.</given-names></name>
<name><surname>Chaudhry</surname><given-names>Q.U.N.</given-names></name>
<name><surname>Satti</surname><given-names>T.M.</given-names></name>
<name><surname>Mahmood</surname><given-names>S.K.</given-names></name>
<name><surname>Ghafoor</surname><given-names>T.</given-names></name>
<name><surname>Shahbaz</surname><given-names>N.</given-names></name>
<name><surname>Khan</surname><given-names>M.A.</given-names></name>
<name><surname>Satti</surname><given-names>H.S.</given-names></name>
<name><surname>Akram</surname><given-names>Z.</given-names></name>
<name><surname>Iftikhar</surname><given-names>R.</given-names></name>
</person-group><article-title>Epidemiology of aplastic anemia: A study of 1324 cases</article-title><source>Hematology</source><year>2020</year><volume>25</volume><fpage>48</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1080/16078454.2019.1711344</pub-id><pub-id pub-id-type="pmid">31906834</pub-id>
</element-citation></ref><ref id="B4-hematolrep-17-00025"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>DeZern</surname><given-names>A.E.</given-names></name>
<name><surname>Churpek</surname><given-names>J.E.</given-names></name>
</person-group><article-title>Approach to the diagnosis of aplastic anemia</article-title><source>Blood Adv.</source><year>2021</year><volume>5</volume><fpage>2660</fpage><lpage>2671</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2021004345</pub-id><pub-id pub-id-type="pmid">34156438</pub-id>
</element-citation></ref><ref id="B5-hematolrep-17-00025"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Camitta</surname><given-names>B.M.</given-names></name>
<name><surname>Rappeport</surname><given-names>J.M.</given-names></name>
<name><surname>Parkman</surname><given-names>R.</given-names></name>
<name><surname>Nathan</surname><given-names>D.G.</given-names></name>
</person-group><article-title>Selection of patients for bone marrow transplantation in severe aplastic anemia</article-title><source>Blood</source><year>1975</year><volume>45</volume><fpage>355</fpage><lpage>363</lpage><pub-id pub-id-type="doi">10.1182/blood.V45.3.355.355</pub-id><pub-id pub-id-type="pmid">1090310</pub-id>
</element-citation></ref><ref id="B6-hematolrep-17-00025"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bacigalupo</surname><given-names>A.</given-names></name>
<name><surname>Hows</surname><given-names>J.</given-names></name>
<name><surname>Gluckman</surname><given-names>E.</given-names></name>
<name><surname>Nissen</surname><given-names>C.</given-names></name>
<name><surname>Marsh</surname><given-names>J.</given-names></name>
<name><surname>Van Lint</surname><given-names>M.T.</given-names></name>
<name><surname>Congiu</surname><given-names>M.</given-names></name>
<name><surname>De Planque</surname><given-names>M.M.</given-names></name>
<name><surname>Ernst</surname><given-names>P.</given-names></name>
<name><surname>McCann</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): A report of the EBMT SAA working party</article-title><source>Br. J. Haematol.</source><year>1988</year><volume>70</volume><fpage>177</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2141.1988.tb02460.x</pub-id><pub-id pub-id-type="pmid">3056497</pub-id>
</element-citation></ref><ref id="B7-hematolrep-17-00025"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Babushok</surname><given-names>D.V.</given-names></name>
<name><surname>DeZern</surname><given-names>A.E.</given-names></name>
<name><surname>de Castro</surname><given-names>C.M.</given-names></name>
<name><surname>Rogers</surname><given-names>Z.R.</given-names></name>
<name><surname>Beenhouwer</surname><given-names>D.</given-names></name>
<name><surname>Broder</surname><given-names>M.S.</given-names></name>
<name><surname>Fanning</surname><given-names>S.R.</given-names></name>
<name><surname>Gibbs</surname><given-names>S.N.</given-names></name>
<name><surname>Hanna</surname><given-names>R.</given-names></name>
<name><surname>Maciejewski</surname><given-names>J.P.</given-names></name>
<etal/>
</person-group><article-title>Modified Delphi panel consensus recommendations for management of severe aplastic anemia</article-title><source>Blood Adv.</source><year>2024</year><volume>8</volume><fpage>3946</fpage><lpage>3960</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2023011642</pub-id><pub-id pub-id-type="pmid">38669341</pub-id>
</element-citation></ref><ref id="B8-hematolrep-17-00025"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Iftikhar</surname><given-names>R.</given-names></name>
<name><surname>Chaudhry</surname><given-names>Q.U.N.</given-names></name>
<name><surname>Anwer</surname><given-names>F.</given-names></name>
<name><surname>Neupane</surname><given-names>K.</given-names></name>
<name><surname>Rafae</surname><given-names>A.</given-names></name>
<name><surname>Mahmood</surname><given-names>S.K.</given-names></name>
<name><surname>Ghafoor</surname><given-names>T.</given-names></name>
<name><surname>Shahbaz</surname><given-names>N.</given-names></name>
<name><surname>Khan</surname><given-names>M.A.</given-names></name>
<name><surname>Khattak</surname><given-names>T.A.</given-names></name>
<etal/>
</person-group><article-title>Allogeneic hematopoietic stem cell transplantation in aplastic anemia: Current indications and transplant strategies</article-title><source>Blood Rev.</source><year>2021</year><volume>47</volume><fpage>100772</fpage><pub-id pub-id-type="doi">10.1016/j.blre.2020.100772</pub-id><pub-id pub-id-type="pmid">33187812</pub-id>
</element-citation></ref><ref id="B9-hematolrep-17-00025"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Weinberger</surname><given-names>M.</given-names></name>
<name><surname>Elattar</surname><given-names>I.</given-names></name>
<name><surname>Marshall</surname><given-names>D.</given-names></name>
<name><surname>Steinberg</surname><given-names>S.M.</given-names></name>
<name><surname>Redner</surname><given-names>R.L.</given-names></name>
<name><surname>Young</surname><given-names>N.S.</given-names></name>
<name><surname>Pizzo</surname><given-names>P.A.</given-names></name>
</person-group><article-title>Patterns of infection in patients with aplastic anemia and the emergence of Aspergillus as a major cause of death</article-title><source>Medicine</source><year>1992</year><volume>71</volume><fpage>24</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1097/00005792-199201000-00003</pub-id><pub-id pub-id-type="pmid">1549057</pub-id>
</element-citation></ref><ref id="B10-hematolrep-17-00025"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Valdez</surname><given-names>J.M.</given-names></name>
<name><surname>Scheinberg</surname><given-names>P.</given-names></name>
<name><surname>Young</surname><given-names>N.S.</given-names></name>
<name><surname>Walsh</surname><given-names>T.J.</given-names></name>
</person-group><article-title>Infections in patients with aplastic anemia</article-title><source>Semin. Hematol.</source><year>2009</year><volume>46</volume><fpage>269</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.1053/j.seminhematol.2009.03.008</pub-id><pub-id pub-id-type="pmid">19549579</pub-id>
</element-citation></ref><ref id="B11-hematolrep-17-00025"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dutta</surname><given-names>B.</given-names></name>
<name><surname>Dolai</surname><given-names>T.K.</given-names></name>
<name><surname>Mandal</surname><given-names>P.K.</given-names></name>
<name><surname>Baul</surname><given-names>S.</given-names></name>
<name><surname>De</surname><given-names>R.</given-names></name>
<name><surname>Senthil</surname><given-names>K.</given-names></name>
<name><surname>Chakrabarti</surname><given-names>P.</given-names></name>
</person-group><article-title>Response to Immunosuppressive Therapy in Acquired Aplastic Anaemia: Experience of a Tertiary Care Centre from Eastern India</article-title><source>Indian. J. Hematol. Blood Transfus.</source><year>2021</year><volume>37</volume><fpage>197</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1007/s12288-019-01158-x</pub-id><pub-id pub-id-type="pmid">33867724</pub-id>
</element-citation></ref><ref id="B12-hematolrep-17-00025"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lionel</surname><given-names>S.A.</given-names></name>
<name><surname>Selvarajan</surname><given-names>S.</given-names></name>
<name><surname>Korula</surname><given-names>A.</given-names></name>
<name><surname>Kulkarni</surname><given-names>U.</given-names></name>
<name><surname>Devasia</surname><given-names>A.</given-names></name>
<name><surname>Abubacker</surname><given-names>F.N.</given-names></name>
<name><surname>Abraham</surname><given-names>A.</given-names></name>
<name><surname>Mathews</surname><given-names>V.</given-names></name>
<name><surname>Lakshmi</surname><given-names>K.M.</given-names></name>
<name><surname>George</surname><given-names>B.</given-names></name>
</person-group><article-title>Profile and Predictors of Infection Following Anti-thymocyte Globulin or Anti-lymphocyte Globulin with Cyclosporine in Aplastic Anemia</article-title><source>Indian. J. Hematol. Blood Transfus.</source><year>2023</year><volume>39</volume><fpage>419</fpage><lpage>428</lpage><pub-id pub-id-type="doi">10.1007/s12288-022-01597-z</pub-id><pub-id pub-id-type="pmid">37304482</pub-id>
</element-citation></ref><ref id="B13-hematolrep-17-00025"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Torres</surname><given-names>H.A.</given-names></name>
<name><surname>Bodey</surname><given-names>G.P.</given-names></name>
<name><surname>Rolston</surname><given-names>K.V.</given-names></name>
<name><surname>Kantarjian</surname><given-names>H.M.</given-names></name>
<name><surname>Raad</surname><given-names>I.I.</given-names></name>
<name><surname>Kontoyiannis</surname><given-names>D.P.</given-names></name>
</person-group><article-title>Infections in patients with aplastic anemia: Experience at a tertiary care cancer center</article-title><source>Cancer</source><year>2003</year><volume>98</volume><fpage>86</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1002/cncr.11478</pub-id><pub-id pub-id-type="pmid">12833460</pub-id>
</element-citation></ref><ref id="B14-hematolrep-17-00025"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Henao-Mart&#x000ed;nez</surname><given-names>A.F.</given-names></name>
<name><surname>Corbisiero</surname><given-names>M.F.</given-names></name>
<name><surname>Salter</surname><given-names>I.</given-names></name>
<name><surname>Chastain</surname><given-names>D.B.</given-names></name>
<name><surname>Thompson</surname><given-names>G.R.</given-names></name>
</person-group><article-title>Invasive pulmonary aspergillosis real-world outcomes: Clinical features and risk factors associated with increased mortality</article-title><source>Med. Mycol.</source><year>2023</year><volume>61</volume><pub-id pub-id-type="doi">10.1093/mmy/myad074</pub-id></element-citation></ref><ref id="B15-hematolrep-17-00025"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marsh</surname><given-names>J.C.W.</given-names></name>
<name><surname>Kulasekararaj</surname><given-names>A.G.</given-names></name>
</person-group><article-title>Management of the refractory aplastic anemia patient: What are the options?</article-title><source>Blood</source><year>2013</year><volume>122</volume><fpage>3561</fpage><lpage>3567</lpage><pub-id pub-id-type="doi">10.1182/blood-2013-05-498279</pub-id><pub-id pub-id-type="pmid">24052548</pub-id>
</element-citation></ref><ref id="B16-hematolrep-17-00025"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Osorio-Arag&#x000f3;n</surname><given-names>I.Y.</given-names></name>
<name><surname>Toussaint-Caire</surname><given-names>S.</given-names></name>
<name><surname>Guzm&#x000e1;n-Bucio</surname><given-names>S.</given-names></name>
<name><surname>Barbosa-Ram&#x000ed;rez</surname><given-names>B.M.</given-names></name>
<name><surname>V&#x000e1;zquez-Aceituno</surname><given-names>V.A.</given-names></name>
<name><surname>Xicohtencatl-Cortes</surname><given-names>J.</given-names></name>
<name><surname>Hern&#x000e1;ndez-Castro</surname><given-names>R.</given-names></name>
</person-group><article-title>Primary cutaneous mucormycosis due to Rhizopus arrhizus in an immunosuppressed patient with paroxysmal nocturnal haemoglobinuria</article-title><source>Trop. Med. Int. Health</source><year>2023</year><volume>28</volume><fpage>580</fpage><lpage>584</lpage><pub-id pub-id-type="doi">10.1111/tmi.13898</pub-id><pub-id pub-id-type="pmid">37230484</pub-id>
</element-citation></ref><ref id="B17-hematolrep-17-00025"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>Z.P.</given-names></name>
<name><surname>Yang</surname><given-names>J.C.</given-names></name>
<name><surname>Ma</surname><given-names>T.</given-names></name>
<name><surname>He</surname><given-names>X.X.</given-names></name>
<name><surname>Gong</surname><given-names>Y.F.</given-names></name>
<name><surname>Xue</surname><given-names>J.</given-names></name>
<name><surname>Xue</surname><given-names>X.Y.</given-names></name>
</person-group><article-title>Idiopathic aplastic anemia with concurrent complications of colonic perforation and mucormycosis: Case report</article-title><source>Heliyon</source><year>2024</year><volume>10</volume><fpage>e34091</fpage><pub-id pub-id-type="doi">10.1016/j.heliyon.2024.e34091</pub-id><pub-id pub-id-type="pmid">39055835</pub-id>
</element-citation></ref><ref id="B18-hematolrep-17-00025"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Solomou</surname><given-names>E.E.</given-names></name>
<name><surname>Gibellini</surname><given-names>F.</given-names></name>
<name><surname>Stewart</surname><given-names>B.</given-names></name>
<name><surname>Malide</surname><given-names>D.</given-names></name>
<name><surname>Berg</surname><given-names>M.</given-names></name>
<name><surname>Visconte</surname><given-names>V.</given-names></name>
<name><surname>Green</surname><given-names>S.</given-names></name>
<name><surname>Childs</surname><given-names>R.</given-names></name>
<name><surname>Chanock</surname><given-names>S.J.</given-names></name>
<name><surname>Young</surname><given-names>N.S.</given-names></name>
</person-group><article-title>Perforin gene mutations in patients with acquired aplastic anemia</article-title><source>Blood</source><year>2007</year><volume>109</volume><fpage>5234</fpage><lpage>5237</lpage><pub-id pub-id-type="doi">10.1182/blood-2006-12-063495</pub-id><pub-id pub-id-type="pmid">17311987</pub-id>
</element-citation></ref><ref id="B19-hematolrep-17-00025"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Saleh</surname><given-names>M.N.</given-names></name>
<name><surname>Bussel</surname><given-names>J.B.</given-names></name>
<name><surname>Cheng</surname><given-names>G.</given-names></name>
<name><surname>Meyer</surname><given-names>O.</given-names></name>
<name><surname>Bailey</surname><given-names>C.K.</given-names></name>
<name><surname>Arning</surname><given-names>M.</given-names></name>
<name><surname>Brainsky</surname><given-names>A.</given-names></name>
</person-group><article-title>Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: Results of the long-term, open-label EXTEND study</article-title><source>Blood</source><year>2013</year><volume>121</volume><fpage>537</fpage><lpage>545</lpage><pub-id pub-id-type="doi">10.1182/blood-2012-04-425512</pub-id><pub-id pub-id-type="pmid">23169778</pub-id>
</element-citation></ref><ref id="B20-hematolrep-17-00025"><label>20.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>de Latour</surname><given-names>R.P.</given-names></name>
<name><surname>Risitano</surname><given-names>A.M.</given-names></name>
<name><surname>Dufour</surname><given-names>C.</given-names></name>
</person-group><article-title>Severe aplastic anemia and PNH</article-title><source>The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies</source><person-group person-group-type="editor">
<name><surname>Carreras</surname><given-names>E.</given-names></name>
<name><surname>Dufour</surname><given-names>C.</given-names></name>
<name><surname>Mohty</surname><given-names>M.</given-names></name>
<name><surname>Kroger</surname><given-names>N.</given-names></name>
</person-group><publisher-name>Springer</publisher-name><publisher-loc>Berlin/Heidelberg, Germany</publisher-loc><year>2019</year><fpage>579</fpage><lpage>585</lpage></element-citation></ref><ref id="B21-hematolrep-17-00025"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bacigalupo</surname><given-names>A.</given-names></name>
<name><surname>Benintende</surname><given-names>G.</given-names></name>
</person-group><article-title>Bone marrow transplantation for acquired aplastic anemia: What&#x02019;s new</article-title><source>Best. Pract. Res. Clin. Haematol.</source><year>2021</year><volume>34</volume><fpage>101284</fpage><pub-id pub-id-type="doi">10.1016/j.beha.2021.101284</pub-id><pub-id pub-id-type="pmid">34404530</pub-id>
</element-citation></ref><ref id="B22-hematolrep-17-00025"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marsh</surname><given-names>J.C.W.</given-names></name>
<name><surname>Risitano</surname><given-names>A.M.</given-names></name>
<name><surname>Mufti</surname><given-names>G.J.</given-names></name>
</person-group><article-title>The Case for Upfront HLA-Matched Unrelated Donor Hematopoietic Stem Cell Transplantation as a Curative Option for Adult Acquired Severe Aplastic Anemia</article-title><source>Biol. Blood Marrow Transplant.</source><year>2019</year><volume>25</volume><fpage>e277</fpage><lpage>e284</lpage><pub-id pub-id-type="doi">10.1016/j.bbmt.2019.05.012</pub-id><pub-id pub-id-type="pmid">31129354</pub-id>
</element-citation></ref><ref id="B23-hematolrep-17-00025"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Peffault de Latour</surname><given-names>R.</given-names></name>
<name><surname>Kulasekararaj</surname><given-names>A.</given-names></name>
<name><surname>Iacobelli</surname><given-names>S.</given-names></name>
<name><surname>Terwel</surname><given-names>S.R.</given-names></name>
<name><surname>Cook</surname><given-names>R.</given-names></name>
<name><surname>Griffin</surname><given-names>M.</given-names></name>
<name><surname>Halkes</surname><given-names>C.J.M.</given-names></name>
<name><surname>Recher</surname><given-names>C.</given-names></name>
<name><surname>Barraco</surname><given-names>F.</given-names></name>
<name><surname>Forcade</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title>Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia</article-title><source>N. Engl. J. Med.</source><year>2022</year><volume>386</volume><fpage>11</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2109965</pub-id><pub-id pub-id-type="pmid">34986284</pub-id>
</element-citation></ref><ref id="B24-hematolrep-17-00025"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lertpongpiroon</surname><given-names>R.</given-names></name>
<name><surname>Rattarittamrong</surname><given-names>E.</given-names></name>
<name><surname>Rattanathammethee</surname><given-names>T.</given-names></name>
<name><surname>Chai-Adisaksopha</surname><given-names>C.</given-names></name>
<name><surname>Tantiworawit</surname><given-names>A.</given-names></name>
<name><surname>Salee</surname><given-names>P.</given-names></name>
<name><surname>Norasetthada</surname><given-names>L.</given-names></name>
</person-group><article-title>Infections in patients with aplastic Anemia in Chiang Mai University</article-title><source>BMC Hematol.</source><year>2018</year><volume>18</volume><elocation-id>35</elocation-id><pub-id pub-id-type="doi">10.1186/s12878-018-0129-9</pub-id><pub-id pub-id-type="pmid">30534380</pub-id>
</element-citation></ref><ref id="B25-hematolrep-17-00025"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thompson</surname><given-names>G.R.</given-names><suffix>3rd</suffix></name>
<name><surname>Young</surname><given-names>J.H.</given-names></name>
</person-group><article-title>Aspergillus Infections</article-title><source>N. Engl. J. Med.</source><year>2021</year><volume>385</volume><fpage>1496</fpage><lpage>1509</lpage><pub-id pub-id-type="doi">10.1056/NEJMra2027424</pub-id><pub-id pub-id-type="pmid">34644473</pub-id>
</element-citation></ref><ref id="B26-hematolrep-17-00025"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dailey Garnes</surname><given-names>N.J.M.</given-names></name>
<name><surname>Kontoyiannis</surname><given-names>D.P.</given-names></name>
</person-group><article-title>Mucormycosis: Update on clinical presentation, diagnosis, and treatment</article-title><source>Curr. Opin. Infect. Dis.</source><year>2023</year><volume>36</volume><fpage>427</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1097/QCO.0000000000000976</pub-id><pub-id pub-id-type="pmid">37732771</pub-id>
</element-citation></ref><ref id="B27-hematolrep-17-00025"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Baddley</surname><given-names>J.W.</given-names></name>
</person-group><article-title>Clinical risk factors for invasive aspergillosis</article-title><source>Med. Mycol.</source><year>2011</year><volume>49</volume><issue>(Suppl. S1)</issue><fpage>S7</fpage><lpage>S12</lpage><pub-id pub-id-type="doi">10.3109/13693786.2010.505204</pub-id><pub-id pub-id-type="pmid">20718606</pub-id>
</element-citation></ref><ref id="B28-hematolrep-17-00025"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Skiada</surname><given-names>A.</given-names></name>
<name><surname>Lass-Floerl</surname><given-names>C.</given-names></name>
<name><surname>Klimko</surname><given-names>N.</given-names></name>
<name><surname>Ibrahim</surname><given-names>A.</given-names></name>
<name><surname>Roilides</surname><given-names>E.</given-names></name>
<name><surname>Petrikkos</surname><given-names>G.</given-names></name>
</person-group><article-title>Challenges in the diagnosis and treatment of mucormycosis</article-title><source>Med. Mycol.</source><year>2018</year><volume>56</volume><fpage>93</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1093/mmy/myx101</pub-id><pub-id pub-id-type="pmid">29538730</pub-id>
</element-citation></ref><ref id="B29-hematolrep-17-00025"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chamilos</surname><given-names>G.</given-names></name>
<name><surname>Kontoyiannis</surname><given-names>D.P.</given-names></name>
</person-group><article-title>Defining the diagnosis of invasive aspergillosis</article-title><source>Med. Mycol.</source><year>2006</year><volume>44</volume><fpage>S163</fpage><lpage>S173</lpage><pub-id pub-id-type="doi">10.1080/13693780600823258</pub-id><pub-id pub-id-type="pmid">30408899</pub-id>
</element-citation></ref><ref id="B30-hematolrep-17-00025"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lass-Fl&#x000f6;rl</surname><given-names>C.</given-names></name>
</person-group><article-title>How to make a fast diagnosis in invasive aspergillosis</article-title><source>Med. Mycol.</source><year>2019</year><volume>57</volume><fpage>S155</fpage><lpage>S160</lpage><pub-id pub-id-type="doi">10.1093/mmy/myy103</pub-id><pub-id pub-id-type="pmid">30816965</pub-id>
</element-citation></ref><ref id="B31-hematolrep-17-00025"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>S&#x000fc;sl&#x000fc;</surname><given-names>A.E.</given-names></name>
<name><surname>O&#x0011f;retmeno&#x0011f;lu</surname><given-names>O.</given-names></name>
<name><surname>S&#x000fc;sl&#x000fc;</surname><given-names>N.</given-names></name>
<name><surname>Y&#x000fc;cel</surname><given-names>O.T.</given-names></name>
<name><surname>Onerci</surname><given-names>T.M.</given-names></name>
</person-group><article-title>Acute invasive fungal rhinosinusitis: Our experience with 19 patients</article-title><source>Eur. Arch. Otorhinolaryngol.</source><year>2009</year><volume>266</volume><fpage>77</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1007/s00405-008-0694-9</pub-id><pub-id pub-id-type="pmid">18470528</pub-id>
</element-citation></ref><ref id="B32-hematolrep-17-00025"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lop-Gros</surname><given-names>J.</given-names></name>
<name><surname>Gras-Cabrerizo</surname><given-names>J.R.</given-names></name>
<name><surname>Bothe-Gonz&#x000e1;lez</surname><given-names>C.</given-names></name>
<name><surname>Montserrat-Gili</surname><given-names>J.R.</given-names></name>
<name><surname>Sumarroca-Trouboul</surname><given-names>A.</given-names></name>
<name><surname>Massegur-Solench</surname><given-names>H.</given-names></name>
</person-group><article-title>Fungus ball of the paranasal sinuses: Analysis of our serie of patients</article-title><source>Acta Otorrinolaringol. Esp.</source><year>2016</year><volume>67</volume><fpage>220</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1016/j.otorri.2015.09.005</pub-id><pub-id pub-id-type="pmid">26708329</pub-id>
</element-citation></ref><ref id="B33-hematolrep-17-00025"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gnanaraj</surname><given-names>J.</given-names></name>
<name><surname>Parnes</surname><given-names>A.</given-names></name>
<name><surname>Francis</surname><given-names>C.W.</given-names></name>
<name><surname>Go</surname><given-names>R.S.</given-names></name>
<name><surname>Takemoto</surname><given-names>C.M.</given-names></name>
<name><surname>Hashmi</surname><given-names>S.K.</given-names></name>
</person-group><article-title>Approach to pancytopenia: Diagnostic algorithm for clinical hematologists</article-title><source>Blood Rev.</source><year>2018</year><volume>32</volume><fpage>361</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1016/j.blre.2018.03.001</pub-id><pub-id pub-id-type="pmid">29555368</pub-id>
</element-citation></ref><ref id="B34-hematolrep-17-00025"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ponnatt</surname><given-names>T.S.</given-names></name>
<name><surname>Lilley</surname><given-names>C.M.</given-names></name>
<name><surname>Mirza</surname><given-names>K.M.</given-names></name>
</person-group><article-title>Hemophagocytic Lymphohistiocytosis</article-title><source>Arch. Pathol. Lab. Med.</source><year>2022</year><volume>146</volume><fpage>507</fpage><lpage>519</lpage><pub-id pub-id-type="doi">10.5858/arpa.2020-0802-RA</pub-id><pub-id pub-id-type="pmid">34347856</pub-id>
</element-citation></ref><ref id="B35-hematolrep-17-00025"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chinnici</surname><given-names>A.</given-names></name>
<name><surname>Beneforti</surname><given-names>L.</given-names></name>
<name><surname>Pegoraro</surname><given-names>F.</given-names></name>
<name><surname>Trambusti</surname><given-names>I.</given-names></name>
<name><surname>Tondo</surname><given-names>A.</given-names></name>
<name><surname>Favre</surname><given-names>C.</given-names></name>
<name><surname>Coniglio</surname><given-names>M.L.</given-names></name>
<name><surname>Sieni</surname><given-names>E.</given-names></name>
</person-group><article-title>Approaching hemophagocytic lymphohistiocytosis</article-title><source>Front. Immunol.</source><year>2023</year><volume>14</volume><elocation-id>1210041</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2023.1210041</pub-id><pub-id pub-id-type="pmid">37426667</pub-id>
</element-citation></ref><ref id="B36-hematolrep-17-00025"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Voskoboinik</surname><given-names>I.</given-names></name>
<name><surname>Whisstock</surname><given-names>J.C.</given-names></name>
<name><surname>Trapani</surname><given-names>J.A.</given-names></name>
</person-group><article-title>Perforin and granzymes: Function, dysfunction and human pathology</article-title><source>Nat. Rev. Immunol.</source><year>2015</year><volume>15</volume><fpage>388</fpage><lpage>400</lpage><pub-id pub-id-type="doi">10.1038/nri3839</pub-id><pub-id pub-id-type="pmid">25998963</pub-id>
</element-citation></ref><ref id="B37-hematolrep-17-00025"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lopez</surname><given-names>J.A.</given-names></name>
<name><surname>Susanto</surname><given-names>O.</given-names></name>
<name><surname>Jenkins</surname><given-names>M.R.</given-names></name>
<name><surname>Lukoyanova</surname><given-names>N.</given-names></name>
<name><surname>Sutton</surname><given-names>V.R.</given-names></name>
<name><surname>Law</surname><given-names>R.H.P.</given-names></name>
<name><surname>Johnston</surname><given-names>A.</given-names></name>
<name><surname>Bird</surname><given-names>C.H.</given-names></name>
<name><surname>Bird</surname><given-names>P.I.</given-names></name>
<name><surname>Whisstock</surname><given-names>J.C.</given-names></name>
<etal/>
</person-group><article-title>Perforin forms transient pores on the target cell plasma membrane to facilitate rapid access of granzymes during killer cell attack</article-title><source>Blood</source><year>2013</year><volume>121</volume><fpage>2659</fpage><lpage>2668</lpage><pub-id pub-id-type="doi">10.1182/blood-2012-07-446146</pub-id><pub-id pub-id-type="pmid">23377437</pub-id>
</element-citation></ref><ref id="B38-hematolrep-17-00025"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rafati</surname><given-names>M.</given-names></name>
<name><surname>McReynolds</surname><given-names>L.J.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Hicks</surname><given-names>B.</given-names></name>
<name><surname>Jones</surname><given-names>K.</given-names></name>
<name><surname>Spellman</surname><given-names>S.R.</given-names></name>
<name><surname>He</surname><given-names>M.</given-names></name>
<name><surname>Bolon</surname><given-names>Y.T.</given-names></name>
<name><surname>Arrieta-Bola&#x000f1;os</surname><given-names>E.</given-names></name>
<name><surname>Saultz</surname><given-names>J.N.</given-names></name>
<etal/>
</person-group><article-title>Hemophagocytic Lymphohistiocytosis Gene Variants in Severe Aplastic Anemia and Their Impact on Hematopoietic Cell Transplantation Outcomes</article-title><source>Transplant. Cell Ther.</source><year>2024</year><volume>30</volume><fpage>770.e1</fpage><lpage>770.e10</lpage><pub-id pub-id-type="doi">10.1016/j.jtct.2024.05.017</pub-id></element-citation></ref><ref id="B39-hematolrep-17-00025"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>P.</given-names></name>
<name><surname>Freidag</surname><given-names>B.L.</given-names></name>
<name><surname>Caldwell</surname><given-names>C.C.</given-names></name>
<name><surname>Seder</surname><given-names>R.A.</given-names></name>
</person-group><article-title>Perforin is required for primary immunity to Histoplasma capsulatum</article-title><source>J. Immunol.</source><year>2001</year><volume>166</volume><fpage>1968</fpage><lpage>1974</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.166.3.1968</pub-id><pub-id pub-id-type="pmid">11160245</pub-id>
</element-citation></ref><ref id="B40-hematolrep-17-00025"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schmidt</surname><given-names>S.</given-names></name>
<name><surname>Condorelli</surname><given-names>A.</given-names></name>
<name><surname>Koltze</surname><given-names>A.</given-names></name>
<name><surname>Lehrnbecher</surname><given-names>T.</given-names></name>
</person-group><article-title>NK Cells and Their Role in Invasive Mold Infection</article-title><source>J. Fungi</source><year>2017</year><volume>3</volume><elocation-id>25</elocation-id><pub-id pub-id-type="doi">10.3390/jof3020025</pub-id></element-citation></ref><ref id="B41-hematolrep-17-00025"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schmidt</surname><given-names>S.</given-names></name>
<name><surname>Tramsen</surname><given-names>L.</given-names></name>
<name><surname>Hanisch</surname><given-names>M.</given-names></name>
<name><surname>Latg&#x000e9;</surname><given-names>J.P.</given-names></name>
<name><surname>Huenecke</surname><given-names>S.</given-names></name>
<name><surname>Koehl</surname><given-names>U.</given-names></name>
<name><surname>Lehrnbecher</surname><given-names>T.</given-names></name>
</person-group><article-title>Human natural killer cells exhibit direct activity against Aspergillus fumigatus hyphae, but not against resting conidia</article-title><source>J. Infect. Dis.</source><year>2011</year><volume>203</volume><fpage>430</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiq062</pub-id><pub-id pub-id-type="pmid">21208932</pub-id>
</element-citation></ref><ref id="B42-hematolrep-17-00025"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schmidt</surname><given-names>S.</given-names></name>
<name><surname>Tramsen</surname><given-names>L.</given-names></name>
<name><surname>Perkhofer</surname><given-names>S.</given-names></name>
<name><surname>Lass-Fl&#x000f6;rl</surname><given-names>C.</given-names></name>
<name><surname>Hanisch</surname><given-names>M.</given-names></name>
<name><surname>R&#x000f6;ger</surname><given-names>F.</given-names></name>
<name><surname>Klingebiel</surname><given-names>T.</given-names></name>
<name><surname>Koehl</surname><given-names>U.</given-names></name>
<name><surname>Lehrnbecher</surname><given-names>T.</given-names></name>
</person-group><article-title>Rhizopus oryzae hyphae are damaged by human natural killer (NK) cells, but suppress NK cell mediated immunity</article-title><source>Immunobiology</source><year>2013</year><volume>218</volume><fpage>939</fpage><lpage>944</lpage><pub-id pub-id-type="doi">10.1016/j.imbio.2012.10.013</pub-id><pub-id pub-id-type="pmid">23201314</pub-id>
</element-citation></ref><ref id="B43-hematolrep-17-00025"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>House</surname><given-names>I.G.</given-names></name>
<name><surname>Thia</surname><given-names>K.</given-names></name>
<name><surname>Brennan</surname><given-names>A.J.</given-names></name>
<name><surname>Tothill</surname><given-names>R.</given-names></name>
<name><surname>Dobrovic</surname><given-names>A.</given-names></name>
<name><surname>Yeh</surname><given-names>W.Z.</given-names></name>
<name><surname>Saffery</surname><given-names>R.</given-names></name>
<name><surname>Chatterton</surname><given-names>Z.</given-names></name>
<name><surname>Trapani</surname><given-names>J.A.</given-names></name>
<name><surname>Voskoboinik</surname><given-names>I.</given-names></name>
</person-group><article-title>Heterozygosity for the common perforin mutation, p.A91V, impairs the cytotoxicity of primary natural killer cells from healthy individuals</article-title><source>Immunol. Cell Biol.</source><year>2015</year><volume>93</volume><fpage>575</fpage><lpage>580</lpage><pub-id pub-id-type="doi">10.1038/icb.2015.1</pub-id><pub-id pub-id-type="pmid">25776844</pub-id>
</element-citation></ref><ref id="B44-hematolrep-17-00025"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Voskoboinik</surname><given-names>I.</given-names></name>
<name><surname>Lacaze</surname><given-names>P.</given-names></name>
<name><surname>Jang</surname><given-names>H.S.</given-names></name>
<name><surname>Flinsenberg</surname><given-names>T.</given-names></name>
<name><surname>Fernando</surname><given-names>S.L.</given-names></name>
<name><surname>Kerridge</surname><given-names>I.</given-names></name>
<name><surname>Riaz</surname><given-names>M.</given-names></name>
<name><surname>Sebra</surname><given-names>R.</given-names></name>
<name><surname>Thia</surname><given-names>K.</given-names></name>
<name><surname>Noori</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>Prevalence and disease predisposition of p.A91V perforin in an aged population of European ancestry</article-title><source>Blood</source><year>2020</year><volume>135</volume><fpage>582</fpage><lpage>584</lpage><pub-id pub-id-type="doi">10.1182/blood.2019003487</pub-id><pub-id pub-id-type="pmid">31932842</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="hematolrep-17-00025-f001"><label>Figure 1</label><caption><p>Bone marrow biopsy. (<bold>A</bold>). Markedly hypocellular bone marrow with stromal edema (hematoxylin-eosin stain; &#x000d7;400). (<bold>B</bold>). The predominant cell population corresponds to T cells (CD3, &#x000d7;400), with rare cytotoxic cells (inset: Granzyme B, &#x000d7;400). (<bold>C</bold>). The arrows depict macrophages with foamy cytoplasm.</p></caption><graphic xlink:href="hematolrep-17-00025-g001" position="float"/></fig><fig position="float" id="hematolrep-17-00025-f002"><label>Figure 2</label><caption><p>Timeline of key clinical events and hematologic parameters.</p></caption><graphic xlink:href="hematolrep-17-00025-g002" position="float"/></fig><fig position="float" id="hematolrep-17-00025-f003"><label>Figure 3</label><caption><p>Neck and chest CT scan. (<bold>A</bold>,<bold>B</bold>). An axial and mid-sagittal image showing a large fluid collection of low attenuation with surrounding rim-enhancement (arrow) and some gaseous foci in the posterior aspect of the nasopharynx (arrow), measuring 3.3 &#x000d7; 4.1 &#x000d7; 2.8 cm, consistent with abscess formation. (<bold>C</bold>,<bold>D</bold>). An axial mid-sagittal image depicting another abscess in the retropharyngeal space (arrow) extending from the level of C2 vertebral body, to the C6 level with a craniocaudal diameter of 6.3 cm and a maximum depth of 1 cm, with a significant fat stranding extending into the visceral and carotid spaces, bilaterally. (<bold>E</bold>,<bold>F</bold>). Axial images depicting a small consolidation in the apicoposterior segment of the left upper lobe (arrow) and a lobar consolidation with ground-glass opacification in the right middle lobe (arrow). (<bold>G</bold>). Axial image showing centrilobular nodules with a linear branching pattern (tree-in-bud) in the lower lobes and in the lingula (arrow). (<bold>H</bold>,<bold>I</bold>) Axial images showing nodules up to 5 mm, some of them with a ground-glass halo, in the lower lobes (arrow), predominantly peripheral in distribution.</p></caption><graphic xlink:href="hematolrep-17-00025-g003" position="float"/></fig><fig position="float" id="hematolrep-17-00025-f004"><label>Figure 4</label><caption><p><italic toggle="yes">Aspergillus</italic> spp. Histopathology. Hyphae with acute branching angle (&#x0003c;45&#x000b0;) or dichotomous branching septate hyphae (blue arrows) and fragments of hyphae (red arrow) (hematoxylin-eosin stain; &#x000d7;400).</p></caption><graphic xlink:href="hematolrep-17-00025-g004" position="float"/></fig></floats-group></article>